SEC Form 4 · accession 0001382963-15-000011

Viridian Therapeutics, Inc.\DE · VRDN

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — President and CEO · Director

Period of report

Apr 8, 2015

Accepted (ET)

Apr 10, 2015 · 5:39 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001590750

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F1	Apr 8, 2015	M	372,756	—	A	372,756	D
Common Stock^F2	Apr 8, 2015	F	119,842	$2.08	D	252,914	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Restricted Stock Units^F1,F3	—	Apr 8, 2015	M	372,756	D	—	—	Common Stock	372,756	372,755	D

F1Restricted stock units converted into common stock on a one-for-one basis.
F2Shares withheld to satisfy tax withholding obligations.
F3On June 17, 2014, the reporting person was granted 745,511 restricted stock units. Under the terms of the restricted stock unit agreement, 372,756 shares were to be delivered to the reporting person on January 1, 2015; however, the issuer and the reporting person agreed to postpone the delivery until April 8, 2015. The remainder of this award will vest as follows: 16-2/3% of the award will vest on the one-year anniversary of the grant date with the vested shares to be delivered to the reporting person on or about the same day; 16-2/3% of the award will vest on the eighteen-month anniversary of the grant date with the vested shares to be delivered to the reporting person on or about the same day; and the remaining 16-2/3 of the award will vest on the two-year anniverary of the grant date with the vested shares to be delivered to the reporting person on or about the same day.